CASRAI Dictionary

Tag: FDA

  • DSCSA Enhanced Drug Traceability: A Process Explainer

    The US Drug Supply Chain Security Act (DSCSA), enacted in 2013, set a ten-year path toward an electronic, interoperable system for tracing prescription drugs through the supply chain. The final phase — often called enhanced drug distribution security — introduced unit-level, serialised, electronic tracing. Because trading partners needed time to make the systems work together, the US Food and Drug Administration (FDA) provided phased stabilisation periods after the November 2024 milestone. This article is a neutral process explainer, not regulatory or legal advice.

    What DSCSA set out to achieve

    DSCSA’s goal is a supply chain in which prescription medicines can be traced electronically at the individual package level, so that suspect or illegitimate products can be identified, quarantined and investigated. The law applies to trading partners across the chain — manufacturers, repackagers, wholesale distributors and dispensers — and built up to its final state through a series of staged requirements over a decade. For the regulatory home of these rules, see our overview of the DSCSA.

    Serialisation: the unique identifier

    The foundation of enhanced traceability is serialisation. Each saleable unit of product carries a product identifier — a standardised code that, when applied at unit level, makes the package uniquely identifiable. A DSCSA product identifier typically combines four data elements:

    • a standardised numerical identifier incorporating the product’s national drug code,
    • a unique serial number,
    • a lot number, and
    • an expiration date.

    These are encoded both in human-readable text and in a machine-readable two-dimensional data-matrix barcode, so the package can be scanned and verified electronically at each handoff. Serialisation is what makes unit-level tracing — as opposed to lot-level tracing — possible.

    Interoperability: electronic and connected

    The final phase requires that tracing be electronic and interoperable. In earlier phases, transaction information could pass between partners in mixed paper and electronic formats. Under enhanced security, the key data — transaction information and transaction statements — must move electronically and in a way that systems across different trading partners can exchange and reconcile. The three traditionally referenced data components are:

    • Transaction information (TI): details of the product and the parties in a sale,
    • Transaction history in earlier phases, and
    • Transaction statement (TS): the seller’s attestation about the product’s legitimacy.

    Interoperability is the hard part because it requires many independent companies’ systems to speak a common language reliably and at scale. That challenge is precisely why the FDA introduced stabilisation periods rather than demanding instant full compliance.

    The stabilisation deadlines

    Recognising that immediate, flawless interoperability across the whole industry was not realistic at the original 2023 milestone, the FDA exercised enforcement discretion to give trading partners more time to stabilise their systems. The result was a set of phased timelines extending past November 2024, with different categories of trading partner — large distributors, dispensers of different sizes, and others — given staggered periods to reach full interoperable exchange. The intent of stabilisation was continuity of supply: avoiding disruptions to patients’ access to medicines while the electronic systems matured.

    The precise dates and partner categories are defined in FDA guidance, and trading partners track the specific timeline that applies to their role. The stabilisation approach is a transition mechanism, not a relaxation of the underlying requirements.

    Who is affected and how roles differ

    DSCSA applies across the chain, but obligations differ by role. Manufacturers and repackagers are responsible for applying the product identifier to packages and for responding to verification requests about identifiers they originated. Wholesale distributors handle large volumes and exchange transaction data with both upstream and downstream partners, making interoperable systems especially important to them. Dispensers — such as pharmacies — receive product and the associated electronic data, and have their own obligations around handling that information and managing suspect product. The staggered stabilisation timelines reflected these different roles and the differing readiness of each segment.

    Because every link in the chain must exchange data with the next, the system only works if partners’ systems can communicate reliably. A single partner unable to send or receive the required electronic information can create friction for others, which is part of why the FDA prioritised continuity of supply during the transition.

    How verification works in practice

    Two everyday mechanisms illustrate the system. First, when a product identifier needs checking — for example, on a suspect product or a saleable return — partners can run a verification against the manufacturer’s records to confirm the identifier is valid. Second, the broader expectation is that suspect and illegitimate product handling is supported by the electronic data, so that questionable products can be quarantined and investigated using a traceable record.

    For readers new to the terminology, our standards dictionary provides neutral definitions of related supply-chain and identifier concepts, and the explainer on persistent identifiers offers useful conceptual parallels to how serialised codes make objects uniquely findable.

    Why the ten-year timeline mattered

    It is worth remembering that DSCSA was deliberately phased over a decade. Earlier milestones introduced lot-level tracing, transaction documentation and authorised-trading-partner requirements, building the foundations on which unit-level serialised tracing could later sit. This staged design reflected the scale of the task: re-engineering how an entire national supply chain identifies, records and exchanges information about prescription medicines. The enhanced phase is the culmination of that build-up, and the stabilisation periods after November 2024 were a recognition that even a decade of preparation left genuine interoperability work to finish. Viewed across the full timeline, the move to electronic, interoperable, package-level tracing is the endpoint of a long, deliberate transition rather than a sudden change.

    The bottom line

    DSCSA’s enhanced phase replaces lot-level, partly paper-based tracing with serialised, electronic, interoperable tracing at the package level, supported by phased stabilisation so the industry could reach full interoperability without disrupting supply. Authoritative detail — including current timelines and guidance — is published by the FDA at fda.gov, which trading partners consult for binding requirements.

  • How FDA Drug Recalls Work: Classes and Process

    A drug recall is the removal or correction of a marketed medical product that is defective or potentially harmful. Recalls are a core mechanism of post-marketing safety: they let problems discovered after approval be addressed quickly. This article explains how recalls are classified and managed from a standards and process perspective; it is not clinical or regulatory advice.

    Who initiates a recall

    Most recalls in the United States are voluntary, carried out by the manufacturer either on its own initiative or at the FDA’s request. The FDA also has authority to require recalls of certain products. Either way, the agency oversees the process, classifies the recall by risk, and monitors that it is carried out effectively.

    The three recall classes

    Class Level of hazard
    Class I A reasonable probability that use will cause serious harm or death.
    Class II Use may cause temporary or medically reversible harm, or the probability of serious harm is remote.
    Class III Use is unlikely to cause harm but the product violates regulations (for example, a labelling or quality defect).

    A related action, market withdrawal, addresses a minor issue not subject to legal action, while a medical device safety alert warns of a risk from a device.

    What triggers a recall

    Recalls can be prompted by manufacturing defects discovered through quality control, contamination, incorrect labelling or dosing information, stability failures, or safety signals detected through pharmacovigilance and adverse-event reporting. The ability to act quickly depends on traceability — the GMP requirement that every batch can be identified and followed through the supply chain.

    How recalls are communicated and tracked

    The FDA publishes recalls in its Enforcement Report and issues public notices for higher-risk cases. Manufacturers must notify distributors and, where appropriate, the public, and demonstrate that affected product has been retrieved or corrected. The recall is closed only when the agency is satisfied it has been effective.

    Why recalls illustrate good record-keeping

    A recall is only possible because of disciplined documentation: batch records, distribution data and a quality system that links a defect back to its source. This is the same logic of provenance and traceability that underpins reproducible research and trustworthy metadata. For the manufacturing-quality foundations, see our Good Manufacturing Practice explainer; for the regulator’s wider role, see the FDA and drug approval.

    Frequently asked questions

    What is a drug recall?

    A drug recall is the removal or correction of a marketed medicine that is defective or potentially harmful, used to address safety or quality problems found after a product reaches the market.

    What are the FDA recall classes?

    Class I covers products that could cause serious harm or death; Class II covers products that may cause temporary or reversible harm; and Class III covers products unlikely to cause harm but that breach regulations.

    Are recalls usually ordered by the FDA?

    Most recalls are voluntary actions by manufacturers, often at the FDA’s request. The agency oversees, classifies and monitors recalls, and has authority to require them for certain products.

    How does traceability make recalls possible?

    Good Manufacturing Practice requires that every batch be identifiable and traceable through the supply chain, so a defect can be tracked to its source and affected product retrieved efficiently.

  • The FDA: Its Role in Drug Approval and the Research Record

    The Food and Drug Administration (FDA) is the United States federal agency responsible for protecting public health by regulating medicines, biological products, medical devices, food and other goods. For research, the FDA matters because its evidence requirements shape how clinical studies are designed, reported and preserved. This explainer describes the agency’s role in approval and the research record; it does not give clinical or regulatory advice.

    What the FDA regulates

    The FDA’s remit is broad, spanning prescription and over-the-counter medicines, vaccines and other biologics, medical devices, diagnostics, and the safety of much of the food supply. Within medicines, specialised centres — such as the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER) — assess applications.

    The drug-approval pathway

    Before a new medicine can be tested in people, a sponsor files an Investigational New Drug (IND) application. Clinical testing then proceeds through the trial phases. To seek approval, the sponsor submits a New Drug Application (NDA) or, for biologics, a Biologics License Application (BLA), presenting the full body of evidence on safety and efficacy. The agency reviews the data, may convene independent advisory committees, and inspects manufacturing sites against Good Manufacturing Practice before granting or refusing approval.

    Evidence standards and transparency

    FDA decisions rest on the quality of the underlying studies. Requirements for adequate and well-controlled investigations have done much to entrench randomisation, blinding and pre-specified analysis as norms. United States law also requires that many trials be registered and their results posted on ClinicalTrials.gov, reinforcing the transparency expectations that journals impose through the ICMJE. In this way a regulator’s rules ripple outward into the published literature.

    The FDA and the research record

    An approved medicine leaves a long evidentiary trail: registered trials, published results, regulatory review documents and post-marketing surveillance. Keeping these elements connected depends on persistent identifiers and consistent metadata — the infrastructure layer that links a study, its data, its authors and its outputs. A national regulator cannot be displaced as the authority on its own decisions, but a research-standards body can explain how its evidence requirements connect to the wider scholarly record. See our explainers on how FDA drug recalls work and Good Manufacturing Practice.

    Frequently asked questions

    What does the FDA do?

    The FDA regulates the safety and effectiveness of medicines, biologics, medical devices and much of the food supply in the United States, including reviewing and approving new medicines before they reach patients.

    What is the difference between an IND and an NDA?

    An Investigational New Drug application allows a sponsor to begin testing a candidate medicine in people; a New Drug Application is the later submission seeking approval to market it, based on the full evidence gathered during trials.

    Does the FDA require clinical trials to be public?

    United States law requires many trials to be registered and to report results on ClinicalTrials.gov. This complements journal requirements for prospective registration and supports transparency across the evidence base.